CLINICAL TRIAL OF AN INDIGENOUS COMPOUND DRUG NISHAAMALKI IN THE MANAGEMENT OF MADHUMEHA VIS-À-VIS DIABETES MELLITUS

*R.K. YADAV **R. MISHRA *** R.P. CHHIPA ****K.C. AUDICHYA
*Assistant Research Officer (Ay.) ** Research Officer (Ay.) *** Research Officer (Ay.) ****Assistant Director In charge
Central Research Institute (Ayurveda), Madhovilas Palace, Amer Road, Jaipur – 302002.

Received: 10/12/2000 Accepted: 9/3/2001

ABSTRACT: A Clinical trial of Indigenous compound drug ‘Nishamalaki’ was carried out in the CRI (Ayurveda) Hospital, Jaipur on the patient of Madhumeha. For this study, patients were randomly divided into two groups of 25 individuals each and they were termed as group A and B. The individuals of group a were administered Nishamalaki in a dose of one gram twice daily along with diet control, the patients were followed every fortnightly. A significant improvement in the symptoms along with lowering of blood glucose level was observed in the individuals of group B, while the individuals of group A responded initially but could not sustain the same.

INTRODUCTION:

Madhumeha, often correlated with Diabetes Mellitus stands as a global problem. Diabetes Mellitus is the most common of the serious metabolic diseases. When a patient presents signs and symptoms attributable to an osmotic diuresis and is found to have hyperglycemia, essentially all the physicians agree that Diabetes is present. It was well known to the ancient Indian Physicians who described not only the sweet taste of urine as one of the major symptoms but also the relationship of the disease with obesity and consequences of bio-chemical abnormalities in the body creating dislipidaemia in the glucose metabolism.

An elaborate description of its clinical features and effective management are seen in classical texts. A number of herbal preparations and plant extracts have been used with varying degree of success in the management of NIDDM. In the present study on herbal preparation viz. Nishamalaki was taken under trial and its effects on clinical features, blood and urine sugar levels was assessed.

MATERIAL AND METHODS:

1. Selection of cases:- Clinical trial of the drug was carried out in the CRI(Ay.). hospital at Jaipur.

Patients belonging to the near by areas of Jaipur were selected to ensure regular follow up.

- Patients were randomly divided in two groups. Group A and B the groups contained 25 patients having at least two follow up. All the patients were between age group of 30 to 70 yrs. Having diagnosed as NIDDM.
- Patients of group – A were administered a placebo (Barley Powder) in a dose of one gram thrice daily for six weeks...
along with diet control and they were followed every Fortnightly.

- Patients of group B were …. Every fortnightly.
- Patients diagnosed as IDDM and individuals having systematic complications were considered unfit for the studies.

H. Parameters for Assessment:

- Clinical parameters: Certain classical sign and symptoms based on the protocol cleared by the respective ethical committee of CCRAS were taken up for study e.g. Prabhumutratra (polyuria), avilamutratra (Turbid urine), Kshudhadhikya (Poly phagia) Trisha (Polydypsia) and Sthaulya (obesity). Symptoms were graded as ‘O’ (Nil), ‘4’ (Mild), ‘7’ (Moderate and ‘10’ as severe

- Sthaulya was assessed on the basis of ponderal index. (cm.kg.)

Pathological parameters :-

- Value of fasting blood sugar and PPBS. (Before and after treatment)
- Urine sugar (Before and after treatment)

Treatment Response:-

Response of the treatment was observed on the basis of improvement in clinical features Blood and Urine sugar levels after one month of therapy.

RESULTS AND OBSERVATION

TABLE NO.1. INCIDENCE OF AGE & SEX

| S.No. | Age group (Yrs.) | Group | Male   | Female |
|-------|------------------|-------|--------|--------|
| 1.    | 31-40            | A     | 5(20%) | 1(4%)  |
|       |                  | B     | 3(12%) |        |
| 2.    | 41-50            | A     | 8(32%) | 3(12%) |
|       |                  | B     | 9(36%) | 2(8%)  |
| 3.    | 51-60            | A     | 3(12%) | 4(16%) |
|       |                  | B     | 5(20%) | 2(8%)  |
| 4.    | 61-70            | A     | -      | 1(4%)  |
|       |                  | B     | 1(4%)  | 3(12%) |

*n= 25 Table shows that most of the patient in both the groups were in the age group of 41-50yrs.

Table No.2-Incidence of dosa prakriti.

| S.No | Prakriti | Group-A | Group-B |
|------|----------|---------|---------|
| 1.   | V        | 1(4%)   | 1(4%)   |
| 2.   | P        | 3(12%)  | 2(8%)   |
| 3.   | K        | 1(4%)   | 2(8%)   |
| 4.   | V-P      | 6(24%)  | 5(20%)  |
| 5.   | V-K      | 6(24%)  | 7(28%)  |
| 6.   | P-K      | 6(24%)  | 7(28%)  |
The table shows that Dvandaja Prakriti was predominant in both groups.

**Table No.3**

**INCIDENCE OF MANASPRAKRITI**

| S.No. | M. Prakriti (on basis of Predominence) | Group - A | Group - B |
|-------|----------------------------------------|-----------|-----------|
| 1.    | Sattva                                 | 9(36%)    | 10(40%)   |
| 2.    | Raja                                   | 15(60%)   | 14(56%)   |
| 3.    | Tama                                   | 1(4%)     | 1(4%)     |

n = 25 Most of the patient have Rajo guna pradhana, Manas Prakriti

**Table No-4-Incidence of severity of symptoms (BT)**

| S.No. | Symptoms       | Group A | Group B |
|-------|----------------|---------|---------|
|       |                | Nil (   ) | Mild (  ) | Mod. (  ) | Severe ( ) | Nil (   ) | Mild (  ) | Mod. (  ) | Severe ( ) |
| 1.    | PradhutaMutra  | 0 (0%)  | 4 (16%) | 18 (72%) | 3 (12%) | 2 (8%) | 5 (20%) | 14 (56%) | 4 (16%) |
| 2.    | Avil Mutrata   | 16 (64%) | 6 (24%) | 2 (8%) | 1 (4%) | 18 (72%) | 5 (20%) | 2 (8%) | 0 (0%) |
| 3.    | Kshudhadhikya  | 0 (0%)  | 7 (28%) | 15 (60%) | 3 (12%) | 6 (24%) | 5 (20%) | 12 (48%) | 2 (8%) |
| 4.    | Trisha         | 1 (4%)  | 8 (32%) | 11 (44%) | 5 (20%) | 3 (12%) | 9 (36%) | 11 (44%) | 2 (8%) |

*n=25; BT-Before Treatment

**Table No-5-Incidence of severity of symptoms (AT)**

| S.No. | Symptoms       | Group A | Group B |
|-------|----------------|---------|---------|
|       |                | Nil (   ) | Mild (  ) | Mod. (  ) | Severe ( ) | Nil (   ) | Mild (  ) | Mod. (  ) | Severe ( ) |
| 1.    | PradhutaMutra  | 1 (4%)  | 12 (48%) | 8 (32%) | 4 (16%) | 2 (8%) | 16 (64%) | 7 (28%) | 0 (0%) |
| 2.    | Avil Mutrata   | 17 (68%) | 8 (32%) | 0 (0%) | 0 (0%) | 20 (80%) | 4 (16%) | 1 (4%) | 0 (0%) |
| 3.    | Kshudhadhikya  | 1 (4%)  | 17 (68%) | 7 (28%) | 0 (0%) | 7 (28%) | 14 (56%) | 3 (12%) | 1 (4%) |
| 4.    | Trisha         | 1 (4%)  | 5 (60%) | 9 (36%) | 0 (0%) | 6 (24%) | 13 (52%) | 6 (24%) | 0 (0%) |

*n=25; AT-After Treatment
Table No. 6 – Mean symptom score (BT & AT)

| S.No. | Symptoms         | Group A          | Group - B         |
|-------|------------------|------------------|------------------|
|       |                  | BT   | AT(1) | AT(2) | BT   | AT(1) | AT(2) |
| 1.    | PradhutaMutra    | 6.88 | 6.40  | 5.80  | 6.32 | 5.36  | 4.52  |
| 2.    | Avil Mutrata     | 1.92 | 1.80  | 1.28  | 1.36 | 1.24  | 0.92  |
| 3.    | Kshudhadhikya    | 6.52 | 5.32  | 4.68  | 4.96 | 4.12  | 3.48  |
| 4.    | Trisha           | 6.36 | 5.40  | 4.92  | 5.32 | 4.68  | 3.76  |

N=25; BT-Before Treatment; After Treatment

Table No -7 Showing significance of the treatment on symptoms (Group B)

| S.No. | Symptoms         | X difference | SD(+) | SE(+) | t    | P   |
|-------|------------------|--------------|-------|-------|------|-----|
| 1.    | PradhutaMutra    | 1.80         | 2.28  | 0.46  | 3.913 | <.001*** |
| 2.    | Avil Mutrata     | 0.44         | 2.68  | 0.54  | 0.814 | <.4  |
| 3.    | Kshudhadhikya    | 1.48         | 2.95  | 0.59  | 2.508 | <.02* |
| 4.    | Trisha           | 1.56         | 2.59  | 0.52  | 3.000 | <.01** |

N= 25;*** Highly significant, ** Significant, *Less significant

Table No -8 Showing significance of the treatment on symptoms (Group A)

| S.No. | Symptoms         | X difference | SD(+) | SE(+) | t    | P   |
|-------|------------------|--------------|-------|-------|------|-----|
| 1.    | PradhutaMutra    | 1.80         | 1.87  | 0.47  | 2.297 | <.05* |
| 2.    | Avil Mutrata     | 0.64         | 2.40  | 0.48  | 1.333 | <.2  |
| 3.    | Kshudhadhikya    | 1.04         | 1.76  | 0.56  | 1.857 | >.1  |
| 4.    | Trisha           | 1.14         | 2.16  | 0.54  | 2.111 | <.05 |

N= 25;*less significant

Table No. 9: Treatment response on sthaulya (Based on ponderal Index)

| S.No | Group | Before treatment | After treatment |
|------|-------|------------------|-----------------|
| 1.   | A (25) | 4.558            | 4.498           |
| 2.   | B(25)  | 4.983            | 4.856           |

The table shows mean ponderal Index (CM/kg.) of both the groups.
### Table no.10; Treatment response on Urine Sugar level (Before & After Treatment)

| S.No | Group | Nil (0) | Mild (+) | Moderate (+ +) | Severe (+ + +) |
|------|-------|---------|----------|----------------|---------------|
| 1    | A (25) BT | 6 (24%) | 7 (28%)  | 10 (40%)       | 2 (8%)        |
|      | AT    | 8 (32%) | 9 (36%)  | 7 (28%)        | 1 (4%)        |
| 2    | B (25) BT | 7 (28%) | 6 (24%)  | 9 (36%)        | 3 (12%)       |
|      | AT    | 10 (40%)| 8 (32%)  | 5 (20%)        | 2 (8%)        |

### Table – 11; Treatment response on Blood sugar level

| S.No | Group | FBS | PPBS |
|------|-------|-----|------|
|      |       | X diff. | SE | t    | p    | X diff. | SE | t    | p    |
| 1    | Group A (n=25) | 13.83 | 12.3 | 1.124 | >.2 | 20.28 | 19.98 | 1.015 | >.3 |
| 2    | Group B (n=25) | 13.96 | 8.08 | 1.178 | <.1* | 18.64 | 13.53 | 1.378 | <.1* |

* less significant

### Table – 12 ; Influence of Prakriti on Blood sugar (Group – B)

| S.No | Prakriti | FBS | PPBS |
|------|----------|-----|------|
|      |          | X diff. | SE | T   | P   | X diff. | SE | T   | P   |
| 1    | Vataja (n=1) | 2.0 | - | - | - | 4.0 | - | - | - |
| 2    | Pittaja (n=1) | 18.5 | 69.25 | .267 | NS | 19.0 | 83.0 | 0.229 | NS |
| 3    | Kaphaja (n=2) | 24.0 | 2.0 | 12.0 | <.001** | 17 | 7.5 | 2.267 | <.1* |
| 4    | V-P (n=5) | 8.4 | 20.84 | 0.40 | >.7 | 15 | 36.18 | 0.414 | <.7 |
| 5    | V-K (n=7) | 24.28 | 11.52 | 2.10 | <.1* | 22 | 19.16 | 1.148 | >.3 |
| 6    | P-K (n=7) | 12.29 | 10.43 | 1.17 | >.2 | 14.29 | 12.47 | 1.145 | >.3 |
| 7    | Sama (n=1) | 14 | - | - | - | - | - | - | - |

*less significant ** highly significant
Table – 13; Influence of Prakriti on Blood sugar (Group – A)

| S.No | Prakriti | FBS   | PPBS  |
|------|----------|-------|-------|
|      |          | X diff. | SE | T | P | X diff. | SE | T | P |
| 1.   | Vataja (n=1) | 30.0 | - | - | - | 50.0 | - | - | - |
| 2.   | Pittaja (n=3) | 10.0 | 47.25 | .212 | NS | 12.0 | 35.3 | 0.338 | NS |
| 3.   | Kaphaja (n=1) | 30.0 | - | - | - | 19.0 | - | - | - |
| 4.   | V-P (n=6) | 1.0 | 14.67 | 0.068 | NS | 7.5 | 23 | 0.326 | NS |
| 5.   | V-K (n=6) | 11.0 | 9.08 | 1.211 | >.3 | 13.66 | 5.72 | 2.388 | <0.05 |
| 6.   | P-K (n=6) | 21.0 | 15.51 | 1.354 | >.3 | 32.83 | 21.64 | 1.517 | >.2 |
| 7.   | Sama (n=2) | 32.5 | 11.75 | 2.765 | >.2 | 39.0 | 25.5 | 1.529 | >.2 |

DISCUSSION:

- The indigenous compound drug Nishamalaki selected for clinical trial is a combination of Haridra (Curcuma longa) and amalaki (Emblica officinalis), also advocated by Vagbhata as a drug of choice for the treatment of prameha. Shamaka properties. Haridra is well known as a blood purifier while the Amalaki has a potent Rasayana effect.

- Group B, in general showed better response to the treatment considering symptomatology and decrease in the level of blood and urine sugar. This indicates the efficacy of drug as hypoglycemic agent.

- Patients with NIDDM have two physiologic defects, abnormal insulin secretion and resistance to insulin action in target tissues.

- Insulin resistance may be due to any one of three general causes; an abnormal insulin molecule, an excessive amount of circulating anti bodies and target tissue defects.

- It may be possible that this medicine may have some role against circulating antagonists and on the target tissue defects. Both the medicines included in the compound have Tridosha shamaka AND Rasayana property. They are acting at the level of Rasa, Agni and Srotas, thus they may exert a positive response on the whole system.

- Response of the treatment was found better among the individuals having Kaphja content in their body constitution, favours the better prognosis of Kaphaja prameha as described in the classics.

- No untoward effect was observed during the period of therapy.
CONCLUSION:-

The drug Nishamalaki seems to be a simple, safe and cost effective remedy for the treatment of Diabetes mellitus. It may not be so useful in the individuals having fasting blood sugar levels above 200 mg%. In such condition oral hypoglycemic agent may be added. Having high safety profile this drug may also be used as adjuvant along with the modern oral hypoglycemic agents.

REFERENCES

1. Charak : Charak samhita, Choukamba publications Varanasi.
2. Davidson: Text book of medicine, ELBS publications
3. G.C.Nanda et al: Nishamalaki in Madhumeha (NIDDM): A clinical study. Journal of Research in Ayurveda and siddha pp-34-40, vol. XIX, No-1-2.
4. Harrison : Principles of internal medicine, 11th Ed. Mc Graw Hill Book Company.
5. Madhavakara: Madhava Nidanam, Choukamba publications, Varanasi

ACKNOWLEDGEMENT:

- Dr. G. Veluchammy, director, C.C.R.A.S, New Delhi.
- Prof. R.H. Singh, head of the department of Panchkarma and Manasroga, Department of Kayachikitsa, IMS, BHU, Varanasi.